Clinical Context and Decision-Making Surrounding Early Discontinuation of Adjuvant Immune Checkpoint Inhibitors in Genitourinary Malignancies: A Real-World Cohort Study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Purpose Adjuvant immune checkpoint inhibitors (ICIs) are increasingly used for genitourinary malignancies after curative-intent surgery; however, real-world treatment persistence and the circumstances surrounding early discontinuation are unclear. We evaluated treatment completion and the clinical circumstances and decision-making surrounding permanent discontinuation. Methods We retrospectively evaluated 39 consecutive patients who were administered adjuvant pembrolizumab for renal cell carcinoma or nivolumab for urothelial carcinoma at a single center from 2022 to 2025; the data cut-off date was October 8, 2026. The primary outcome was the completion of a planned 1-year treatment among patients with a definitive completion status. The two cohorts were analyzed descriptively without direct comparison. Results Of 37 patients with a definitive treatment status, 20 completed planned therapy (54.1%; 95% confidence interval, 36.9–70.5%) and 17 permanently discontinued treatment before completion (45.9%). The remaining two patients (5.1% of 39) were still on treatment at data cut-off. An adverse event was the documented primary reason for discontinuation in 12 of 17 patients (70.6%); 11 of these 12 (91.7%) followed Grade 1–2 events. Patient preference contributed to nine of 17 discontinuations (52.9%) through patient-initiated or shared decision-making. Grade ≥ 3 adverse events occurred in two patients (5.1%). Conclusions In this retrospective cohort, permanent discontinuation of adjuvant ICI therapy was frequently documented in association with low-grade toxicity and with patient preference, whereas Grade ≥ 3 toxicity was uncommon. Shared decision-making that balances anticipated recurrence-risk reduction against treatment burden represents an important consideration in individualizing adjuvant immunotherapy.
Source: Research Square
Institutions: Jichi Medical University Hospital, The University of Tokyo
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7226024643
